CD248 (Endosialin) Antibody, anti-human, REAfinity™
Synonyms: Tumor endothelial marker 1, CD164L1, CD164 sialomucin-like 1, TEM1
RECOMBINANT
Clone:
REA1344 | B1/35
Type of antibody:
Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MICS, IF, IHC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for CD248 (Endosialin) Antibody, anti-human, REAfinity™

Flow cytometry applications
APC
PE
Vio Bright B515
Vio Bright R720
Vio Bright V423
Vio Bright V600
Recommended dilution:
1:50
Remark:
Cells should be stained prior to fixation, if formaldehyde is used as a fixative.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-133-444, 130-133-470
Description:
BJ cells were then stained with CD248 (Endosialin) antibodies or with the corresponding REA Control (S) antibodies (left peak) and analyzed by flow cytometry using the MACSQuant® Analyzer. The Tandem Signal Enhancer has been used to increase binding specificity of tandem-dye–conjugated antibodies. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence or 4',6-diamidino-2-phenylindole (DAPI) fluorescence, as in the case of tandem conjugates.

Application image
MICS (MACSima Imaging Cyclic Staining) applications
PE
Fixation:
FFPE
Species tested:
human
Tissue used:
breast
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
PE
Used products:
130-133-448, 130-133-473
Testing grade:
Description:
Immunofluorescence analysis of a formalin-fixed, paraffin embedded (FFPE) human breast. Before staining, antigens were retrieved using heat-induced epitope retrieval (HIER) at pH 9. The section was stained using CD248 (Endosialin) Antibody, anti-human, PE (green) for 10 min at room temperature. Nuclei were visualized with Hoechst™ (blue). Scale bar: 30 µm.

Application image
Fixation:
frozen – PFA
Species tested:
human
Tissue used:
breast
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
PE
Used products:
130-133-448, 130-133-473
Testing grade:
Description:
Immunofluorescence analysis of a human breast cryosection fixed with 4% PFA. The section was stained using CD248 (Endosialin) Antibody, anti-human, PE (green) for 10 min at room temperature. Nuclei were visualized with Hoechst™ (blue). Scale bar: 30 µm.

Application imageView details view details

Application imageView details view details
Specifications for CD248 (Endosialin) Antibody, anti-human, REAfinity™
Overview

Clone REA1344 recognizes the human CD248 antigen, also known as Endosalin, Tumor endothelial marker 1 (TEM1) or CD164 sialomucin-like 1 (CD164L1). CD248 is a single-pass type I transmembrane glycoptrotein belonging to the Group XIV, a novel family of C-type lectin transmembrane receptors. CD248 is expressed on tumor endothelial cells, in metastatic lesions of the liver pericytes and on stromal fibroblasts. CD248 is suggested to be involved in tumor angiogenesis,development and growth and in lymphoid tissue organization.

REA1344 displays negligible binding to Fc receptors.

Alternative names

Tumor endothelial marker 1, CD164L1, CD164 sialomucin-like 1, TEM1

Detailed product information

Technical specifications

Clone
REA1344
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (S), human IgG1
Host
human cell line
Type of antibody
Recombinant antibodies
Species reactivity
human
Antigen
CD248 (Endosialin)
Molecular mass of antigen [kDa]
79,1
Distribution of antigen
tumor cells, fibroblasts, other
Entrez Gene ID

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CD248 (Endosialin) Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

Citations for CD248 (Endosialin) Antibody, anti-human, REAfinity™
Publications
  1. Simonavicius, N. et al. (2008) Endosialin (CD248) is a marker of tumor-associated pericytes in high-grade glioma. Mod Pathol 21 (3): 308-315
  2. Rettig, W. J. (1992) Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc. Natl. Acad. Sci. U.S.A. 89 (22): 10832-10836
  3. Khan, K. A. et al. (2019) C-type lectin domain group 14 proteins in vascular biology, cancer and inflammation. FEBS J. 286 (17): 3299-3332
  4. MacFadyen, J. R. et al. (2005) Endosialin (TEM1, CD248) is a marker of stromal fibroblasts and is not selectively expressed on tumour endothelium. FEBS Lett. 579 (12): 2569-2575
  5. Viski, C. et al. (2016) Endosialin-Expressing Pericytes Promote Metastatic Dissemination. Cancer Res. 76 (18): 5313-5325